Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + CAPOX in Perioperative MSI-H/dMMR Stage II/III Colorectal Cancer
NCT05841134Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in colorectal cancer (CRC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pathological Complete Response up to 24 months. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05841134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841134.